title: [Risk of thromboembolism and arteriosclerosis in women].
abstract: Young women are at a 3-fold higher risk of experiencing venous thromboembolism compared to young men. This risk is further increased by oral contraceptives, smoking, hereditary thrombophilia and/or low socioeconomic status. There are also hints for gender-specific differences in the arterial system. Coronary heart disease which is particularly important, develops in women 10-15 years later than in men. However, the clinical course in women is often more complicated. In women, thrombophilic predispositions play a more important role before menopause and metabolic risk factors after menopause compared to men. Thrombus formation needs to be initiated by disturbances of at least one element of the Virchow trias. There is principally no difference between men and women. However, all three elements are influenced by estrogen, resulting in gender-specific differences. There is a favorable influence on blood flow by the inhibition of atherogenesis and on the endothelial function by increased NO release, and the unfavorable influence on hemostasis resulting in hypercoagibility. Thus, particularly non-selective hormone replacement therapy for the inhibition of atherogenesis may be questionable due to increased thrombogenicity. The solution may be more selective estrogen receptor modulators. Clinical trials are still needed for both hormone replacement therapy and the therapy of venous and arterial thromboembolism, which have been studied in predominantly male patient cohorts so far.
authors.affiliation: Medizinische Klinik und Poliklinik C Universitätsklinikum 48129 Münster, Germany. nikol@uni-muenster.de
authors.forename: S
authors.initials: S
authors.lastname: Nikol
authors.forename: K
authors.initials: K
authors.lastname: Middendorf
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D001161:Arteriosclerosis / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D012306:Risk; D013923:Thromboembolism / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control